November 09, 2010 5:33pm EST
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE Amex: OPK) announced today that management and
the Audit Committee of the Company's Board of Directors concluded that
the Company's previously issued consolidated financial statements as of
and for the year ended December 31, 2009, and interim condensed
consolidated financial statements for the quarterly and year-to-date
periods ended September 30, 2009 and as of March 31, 2010 and June 30,
2010 should not be relied upon due to improper accounting treatment of
its Series D Convertible Preferred Stock issued in September 2009 (the
"Preferred Stock").
To properly account for the Preferred Stock, the Company has restated
its previously issued consolidated financial statements as of and for
the year ended December 31, 2009, and interim condensed consolidated
financial statements for the quarterly and year-to-date periods ended
September 30, 2009 and as of March 31, 2010 and June 30, 2010, in
amendments to its Annual Report on Form 10-K for the year ended December
31, 2009, and its Quarterly Reports on Form 10-Q for the interim
quarterly periods ended March 31, 2010 and June 30, 2010, which will be
filed today with the SEC. The adjustments will result in changes to the
Company's balance sheets at December 31, 2009, March 31, 2010 and June
30, 2010, and the Company's statement of operations for the quarter and
nine months ended September 30, 2009, and the year ended December 31,
2009, but will have no impact on the Company's cash or results from
operations. For more information please see the Company's Current Report
on Form 8-K also filed today with the SEC.
The Company's restated consolidated financial statements will reflect
Condensed Consolidated Summary Balance Sheets Information as of
December 31, 2009 March 31, 2010 June 30, 2010
(in As reported Adjustment Restated As reported Adjustment Restated As reported Adjustment Restated
thousands)
Total $ 29,703 $ - $ 29,703 $ 31,059 $ - $ 31,059 $ 17,962 $ - $ 17,962
Liabilities
Series D
Preferred - 26,128 26,128 - 26,128 26,128 - 26,128 26,128
Stock
Shareholders'
equity
Series A
Preferred 10 - 10 10 - 10 10 - 10
Preferred 12 (12 ) 0 12 (12 ) 0 12 (12 ) 0
Stock
Common Stock 2,538 - 2,538 2,552 - 2,552 2,553 - 2,553
Treasury (61 ) - (61 ) (61 ) - (61 ) (61 ) - (61 )
Stock
Additional
paid-in 393,144 (26,116 ) 367,028 396,338 (26,116 ) 370,222 397,898 (26,116 ) 371,782
capital
Accumulated (339,229 ) - (339,229 ) (343,976 ) - (343,976 ) (350,251 ) - (350,251 )
deficit
Cumulative
translation 1,313 - 1,313 969 - 969 (108 ) - (108 )
adjustment
Total
shareholders' 57,727 (26,128 ) 31,599 55,844 (26,128 ) 29,716 50,053 (26,128 ) 23,935
and $ 87,430 $ - $ 87,430 $ 86,903 $ - $ 86,903 $ 68,015 $ - $ 68,015
Condensed Consolidated Summary Statements of Operations Information
For the three months ended For the nine months ended
For the year ended December 31, 2009
September 30, 2009 September 30, 2009
Net loss $ (6,354 ) $ - $ (6,354 ) $ (21,027 ) $ - $ (21,027 ) $ (30,113 ) $ - $ (30,113 )
Preferred
stock (72 ) (3,872 ) (3,944 ) (188 ) (3,872 ) (4,060 ) (846 ) (3,872 ) (4,718 )
dividend
Net loss
attributable $ (6,426 ) (3,872 ) $ (10,298 ) $ (21,215 ) (3,872 ) $ (25,087 ) $ (30,959 ) (3,872 ) $ (34,831 )
to common
shareholders
Basic and
diluted loss $ (0.03 ) $ (0.02 ) $ (0.04 ) $ (0.09 ) $ (0.02 ) $ (0.11 ) $ (0.13 ) $ (0.02 ) $ (0.15 )
per hare
Weighted
average
number of
common 252,986,149 252,986,149 226,273,290 226,273,290 233,191,617 233,191,617
shares
outstanding,
basic and
diluted
About OPKO Health, Inc.
Miami-based OPKO is a specialty healthcare company involved in the
discovery, development, and commercialization of proprietary
pharmaceutical products, medical devices, vaccines, diagnostic
technologies and imaging systems. Initially focused on the treatment and
management of ophthalmic diseases, OPKO has since expanded into other
areas of major unmet medical need.
Forward-Looking Statements
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding, among others, those related to
the timing of the completion of the restatement of the Company's
financial statements, and the filing of amended reports on Forms 10-Q/A
and 10-K/A. Many factors could cause our actual activities or results to
differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described in our
filings with the Securities and Exchange Commission, as well as risks
inherent in financial restatements. In addition, forward-looking
statements may also be adversely affected by general market factors,
competitive product development, product availability, federal and state
regulations and legislation, the regulatory process for new products and
indications, manufacturing issues that may arise, patent positions and
litigation, among other factors. The forward-looking statements
contained in this press release speak only as of the date the statements
were made, and we do not undertake any obligation to update
forward-looking statements, except as required by law. We intend that
all forward-looking statements be subject to the safe-harbor provisions
of the PSLRA.
Source: OPKO Health, Inc.
Released November 9, 2010
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page